Announcements Trials

Browse Landscape

Phase

Status

Completed 9 Terminated 2 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 48 Lymphoid 11 Other hematologic neoplasm 7 Thoracic 3 Genitourinary 3 CNS 3 Sarcoma 1 Other 1 Myeloid 1 Gastrointestinal 1 Dermatologic 1

Conditions

Interventions

Nivolumab 18 Ipilimumab 16 pembrolizumab 15 Cyclophosphamide 13 trametinib 9 Radiotherapy 8 dabrafenib 6 Interleukin-2 6 sargramostim 5 fludarabine phosphate 5 aldesleukin 5 Vemurafenib 5 Peripheral Blood Stem Cell Transplantation 5 Fluorouracil 5 130-nm albumin-bound paclitaxel 5 fludarabine 4 Radiosurgery 4 Melphalan 4 Celecoxib 4 encorafenib 3 durvalumab 3 binimetinib 3 avelumab 3 Vorinostat 3 Specimen Handling 3 Magnetic Resonance Spectroscopy 3 Leucovorin 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Cytarabine 3 Capecitabine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Dexamethasone × Dermatologic × Clear all

NCT02862145 2016-09-27

MRX34-102

Mirna Therapeutics, Inc.

Phase 1/2 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡